Clinical trials: Psychosis; Acute
Psychotic Disorders, Schizophrenia
FAST-A Study to Evaluate the Efficacy and Safety of Quetiapin IR in Patients With Acute Psychosis
The purpose of this study is to compare the efficacy of quetiapine IR, following rapid titration versus conventional titration in patients with acute psychosis
- Conditions
- Psychotic Disorders, Schizophrenia, Bipolar Disorder
- Trial name
- FAST (NCT00486798)
- Testing
- Quetiapine, Rating Scales, Self Assessment Form
- Where
- 13 sites in Sweden
- Sponsor
- AstraZeneca
Schizophrenia
A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia
The purpose of this clinical trial is to learn whether the investigational drug LTX-001 is safe and well tolerated in adults with a diagnosis of schizophrenia who are having a recent worsening of their symptoms (an acute…
- Trial name
- NCT07734493
- Testing
- LTX-001 once daily, LTX-001 twice daily
- Where
- 10 sites in United States
- Volunteers
- 90 people
- Sponsor
- Leal Therapeutics, Inc
Schizophrenia, Mania
A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis
To assess the efficacy, safety, and tolerability of intramuscular ziprasidone in the treatment of the acute exacerbation of non-organic psychosis of any etiology, including schizophrenia, acute mania, delusional disorder and…
- Conditions
- Schizophrenia, Mania, Delusional Disorder, Acute Exacerbation of Psychosis
- Trial name
- NCT00644800
- Testing
- Ziprasidone
- Where
- 8 sites in Brazil
- Volunteers
- 89 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Acute Schizophrenia, Schizoaffective Disorder
RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.
- Trial name
- REFRESH (NCT01490086)
- Testing
- RP5063, aripiprazole
- Where
- 15 sites in United States, India and 3 more
- Volunteers
- 234 people
- Sponsor
- Reviva Pharmaceuticals
Schizophrenia
Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis
A controlled, randomized study on the treatment of schizophrenic psychosis with cannabidiol, a phytocannabinoid is performed. This approach is based upon recent findings indicating that the human endogenous cannabinoid system is…
- Trial name
- CBD-CT1 (NCT00628290)
- Testing
- Cannabidiol, Amisulpride
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- University of Cologne
Schizophrenia
Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia
This is a study designed to evalute the safety and efficacy of RGH-188 in the treatment of acute schizophrenia. This study will be 10 weeks in duration; 6 weeks double-blind treatment, and 4 weeks safety follow-up.
- Trial name
- NCT00404573
- Testing
- RGH-188
- Where
- United States
- Volunteers
- 375 people
- Sponsor
- Forest Laboratories